The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Robinson Chandler since 2021.
This trader's CIK number is 1727334.
At the time of last reporting, Robinson Chandler was the Chief Executive Officer of Monopar Therapeutics. (stock ticker symbol MNPR).
Also see all insider trading activities at Monopar Therapeutics.
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2025 | MNPR | 0 | $0 | 0 | $0 | 23,452 | $0 |
2024 | MNPR | 0 | $0 | 0 | $0 | 85,043 | $0 |
2023 | MNPR | 0 | $0 | 0 | $0 | 114,694 | $0 |
2022 | MNPR | 0 | $0 | 0 | $0 | 52,399 | $0 |
2021 | MNPR | 0 | $0 | 0 | $0 | 18,548 | $0 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2025-06-30 | MNPR | Option Ex | 13,344 | .00 | 0 |
2025-03-31 | MNPR | Option Ex | 4,106 | .00 | 0 |
2025-03-04 | MNPR | Option Ex | 6,002 | .00 | 0 |
2024-09-30 | MNPR | Option Ex | 4,895 | .00 | 0 |
2024-06-30 | MNPR | Option Ex | 24,476 | .00 | 0 |
2024-03-31 | MNPR | Option Ex | 24,474 | .00 | 0 |
2023-12-31 | MNPR | Option Ex | 24,474 | .00 | 0 |
2024-01-01 | MNPR | Option Ex | 6,724 | .00 | 0 |
2023-09-30 | MNPR | Option Ex | 24,474 | .00 | 0 |
2023-06-30 | MNPR | Option Ex | 35,039 | .00 | 0 |
2023-03-31 | MNPR | Option Ex | 13,911 | .00 | 0 |
2023-01-01 | MNPR | Option Ex | 6,723 | .00 | 0 |
2022-12-31 | MNPR | Option Ex | 13,912 | .00 | 0 |
2023-01-01 | MNPR | Option Ex | 6,723 | .00 | 0 |
2022-12-31 | MNPR | Option Ex | 13,912 | .00 | 0 |
2022-09-30 | MNPR | Option Ex | 13,911 | .00 | 0 |
2022-06-30 | MNPR | Option Ex | 23,882 | .00 | 0 |
2022-03-31 | MNPR | Option Ex | 3,941 | .00 | 0 |
2022-01-01 | MNPR | Option Ex | 6,724 | .00 | 0 |
2021-12-31 | MNPR | Option Ex | 3,941 | .00 | 0 |
2021-09-30 | MNPR | Option Ex | 3,941 | .00 | 0 |
2021-06-30 | MNPR | Option Ex | 7,883 | .00 | 0 |
2021-01-01 | MNPR | Option Ex | 6,724 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Robinson Chandler (Chief Executive Officer of Monopar Therapeutics at the time of this reporting) see the Securities and Exchange Commission (SEC) website.